|
Synonyms: M70 | NGM-282 | NGM282
Compound class:
Peptide or derivative
Comment: Aldafermin (NGM282) is a recombinant, engineered analogue of FGF-19 (FGF19-mimetic) that was developed by NGM Biopharmaceuticals. Acting via the FGFR4-β-Klotho (KLB) receptor complex, aldafermin acts to suppress cholesterol 7α-hydroxylase (CYP7A1), the first and rate-limiting enzyme for bile acids biosynthesis.
|
| References |
|
1. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L et al.. (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 391 (10126): 1174-1185. [PMID:29519502] |
|
2. Sanyal AJ, Ling L, Beuers U, DePaoli AM, Lieu HD, Harrison SA, Hirschfield GM. (2021)
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Rep, 3 (3): 100255. [PMID:33898959] |
|
3. Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T et al.. (2014)
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res, 74 (12): 3306-16. [PMID:24728076] |
